Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 8/20 | 0.43 |
| ▸ | CA2 | P00918 | 8/20 | 0.43 |
| ▸ | CA9 | Q16790 | 8/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | LPL | P06858 | 4/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16023158 | 0.87 | DGAT1 (0.43) | DGAT1CA1CA2CA9CA12 | |
| SCHEMBL18426166 | 0.80 | DGAT1 (0.46) | DGAT1CA1CA2CA9CA12 | |
| SCHEMBL29789624 | 0.80 | CA1 (0.45) | DGAT1CA1CA2CA9CA12 | |
| SCHEMBL2596044 | 0.80 | CA1 (0.45) | DGAT1CA1CA2CA9CA12 | |
| SCHEMBL18464663 | 0.79 | DGAT1 (0.48) | DGAT1CA1CA2CA9CA12 | |
| SCHEMBL16014422 | 0.79 | DGAT1 (0.45) | DGAT1CA1CA2CA9CA12 | |
| SCHEMBL2340658 | 0.79 | CA1 (0.51) | CA1CA2CA9CA12CA3 | |
| SCHEMBL16014673 | 0.76 | CA1 (0.42) | DGAT1CA1CA2CA9CA12 | |
| SCHEMBL14247525 | 0.75 | ALPL (0.41) | DGAT1CA1CA2CA9CA12 | |
| SCHEMBL16014773 | 0.75 | LMNA (0.40) | DGAT1CA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964633-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-04-19 | — | — | EP | disclosed |
| EP-2964633-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-04-19 | — | — | EP | disclosed |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2017-03-23 | — | — | US | disclosed |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2017-03-23 | — | — | US | disclosed |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2017-03-23 | — | — | US | disclosed |
| US-9540345-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540345-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540345-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9249163-B2 | PDE10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV. (BE) | 2016-02-02 | — | — | US | disclosed |
| US-9249163-B2 | PDE10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV. (BE) | 2016-02-02 | — | — | US | disclosed |
| US-9249163-B2 | PDE10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV. (BE) | 2016-02-02 | — | — | US | disclosed |
| EP-2964633-A1 | ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-24 | — | — | US | disclosed |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
| WO-2014135471-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135471-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | DGAT1 1448/4885CA1 4795/4885CA2 4807/4885 |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | DGAT1 1448/4885CA1 4795/4885CA2 4807/4885 |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | PDE2A, PDE3B, PDE3A | DGAT1 1073/4885CA1 3580/4885CA2 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.